---
title: "CHINAGREEN BIO: The company has not yet started research and development in the field of synthetic biology"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263188130.md"
description: "CHINAGREEN BIO stated on the interactive platform on October 29 that its Guangxi subsidiary's main products are enoki mushrooms and king oyster mushrooms, which enjoy tax incentives for agricultural products. The company continues to pay attention to the field of synthetic biology but has not yet started research and development in this area"
datetime: "2025-10-29T00:55:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263188130.md)
  - [en](https://longbridge.com/en/news/263188130.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263188130.md)
generator: "portal-rs"
---

# CHINAGREEN BIO: The company has not yet started research and development in the field of synthetic biology

CHINAGREEN BIO stated on the interactive platform on October 29 that the main products of its Guangxi subsidiary are enoki mushrooms and king oyster mushrooms, which enjoy tax incentives for agricultural products. The company continues to pay attention to the field of synthetic biology but has not yet started research and development in this area

### Related Stocks

- [300970.CN](https://longbridge.com/en/quote/300970.CN.md)

## Related News & Research

- [12:04 ET90 Days of Cheaper Beef Could Cost American Ranchers - Good Ranchers Response to New Beef Import Plan](https://longbridge.com/en/news/297351162.md)
- [China Vanke Board Approves 2026 Interim Results, Withholds Mid-Year Dividend](https://longbridge.com/en/news/297187897.md)
- [Fonterra Lifts Milk Collections as Global Dairy Demand Shifts](https://longbridge.com/en/news/297463758.md)
- [ByHeart Says FDA Confirms Review Of ByHeart's Root Cause Investigation And Action Plan](https://longbridge.com/en/news/297358769.md)
- [My Mountain Mover Recognized Among the 2026 Inc. 5000 Fastest-Growing U.S. Companies](https://longbridge.com/en/news/297087696.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**